Filing identity and reporting period
The supplied filing is MEI Pharma, Inc.’s Form 10-K for the fiscal year ended June 30, 2014, filed September 8, 2014. It does not appear to be a filing for “Lite Strategy, Inc.” or for 2012 Q4; the source text identifies MEI Pharma and reports fiscal-year results. The summary below reflects the filing actually supplied.
Business context
MEI Pharma is a clinical-stage oncology company with no operating revenue. Its principal program was Pracinostat, in three Phase II trials for hematologic cancers. The pipeline also included ME-344, in Phase Ib development, and PWT143, then in preclinical development. The company relied on equity financing and external contractors for research, trials, and manufacturing.
Financial performance and liquidity
| Metric | FY ended June 30, 2014 | FY ended June 30, 2013 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $19.3 million | $6.1 million |
| General and administrative expense | $7.9 million | $5.1 million |
| Total operating expenses / operating loss | $27.2 million | $11.2 million |
| Net loss | $27.1 million | $11.2 million |
| Basic and diluted loss per share | $1.35 | $1.10 |
| Net cash used in operations | $19.5 million | $10.0 million |
| Cash, cash equivalents and short-term investments at year-end | $48.8 million | $35.6 million |
Net loss widened substantially, principally as R&D spending increased with Pracinostat Phase II trials and spending on ME-344 and PWT143. No meaningful revenue margin is available because the company had no operating revenue. Cash and cash equivalents alone were $13.8 million at June 30, 2014; short-term investments were $35.0 million. Current assets were $49.3 million versus current liabilities of $4.6 million. Total liabilities were $4.6 million, consisting of accounts payable and accrued liabilities; the balance sheet reports no debt. Management said available cash and investments should fund operations for at least 12 months, while noting that future financing may be needed.
Material changes and financing
- R&D expense rose $13.2 million year over year; G&A increased $2.8 million. Share-based compensation also increased, to $4.7 million from $1.5 million.
- Operating cash use increased by $9.4 million. Net cash from financing was $32.7 million, mainly from the October 2013 stock offering; the company issued 4.375 million shares and reported $32.7 million in net proceeds.
- Cash and cash equivalents fell by $21.8 million during the year, while $35.0 million was invested in short-term investments.
- Shares outstanding increased from 17.1 million to 21.6 million. Outstanding warrants, options, and restricted stock units represented potential additional dilution.
Outlook, risks, and unusual items
- Management expected R&D expense to increase in FY2015, primarily due to clinical trials, and anticipated ongoing operating losses and negative operating cash flows.
- In August 2014, after fiscal year-end, the company completed enrollment of 108 patients in a randomized Phase II Pracinostat-plus-azacitidine MDS trial; topline data were expected by Q1 2015 after six months of follow-up. The filing also described preliminary AML-trial responses and expected further data in December 2014.
- Pracinostat received FDA orphan-drug designation for AML in February 2014. This offers certain development incentives and potential exclusivity if approved, but is not marketing approval.
- Key risks include clinical-trial failure or delay, regulatory uncertainty, competition, dependence on third-party manufacturers and research providers, need for additional financing, and potential dilution. The company disclosed up to $75.2 million in contingent milestone payments to S*Bio, plus potential sales-based earnouts; no such future amounts were accrued at year-end.
- The company reported no off-balance-sheet arrangements and no legal proceedings. The independent auditor issued an unqualified opinion on the financial statements and internal control over financial reporting.
Important facts for investors to verify
- Confirm the intended issuer and reporting period: the supplied document is MEI Pharma’s FY2014 10-K, not a Lite Strategy 2012 Q4 filing.
- Check the full audited statements and subsequent filings for cash runway, spending, and any financing after June 30, 2014.
- Track the stated Pracinostat trial readouts and later clinical updates; early-stage response data do not establish efficacy or approval prospects.
- Review potential dilution from outstanding warrants, options, restricted stock units, and the company’s effective shelf registration.
- Review the detailed terms and triggers for S*Bio milestones and CyDex license and supply obligations.